Post-marketing surveillance results of Pfizer Korea’s breast cancer treatment ‘Ibrance Cap (palbociclib)’ showed an adverse event rate of 86.01% for the drug.

The Ministry of Food and Drug Safety prepared a label change order (draft) items based on its reevaluation results and will be conducting an opinion inquiry until the 5th of next month.

The results of the post-marketing surveillance study conducted by Pfizer on 293 people for 6 years for its reevaluation showed that Ibrance’s reported adverse event rate was 86.01% (252/293 people, 642 cases), regardless of a causal relationship.

Of these, 2.73% (8/293 patients, 11 cases) were serious adverse reactions (ADRs) whos